European Grid Initiative Sample Clauses

European Grid Initiative. Aside from the large user community and impressive use, the production grid infrastructure has had many notable successes. It has allowed scientists from all over Europe and indeed from all over the world federate their computing re-­‐ sources to advance their scientific aims. More importantly, the infrastructure al-­‐ lows them to federate their data and expertise to accomplish more than they would be able to do singlehandedly. Common APIs and service interfaces make it possible to take advantage of these distributed resources without having to modify applications for each site. Despite its success, the grid also has its limitations. The uniformity of service interfaces unfortunately does not extend to the underlying computing resources, where users are exposed to significant heterogeneities in the computing envi-­‐ ronment, complicating applications and increasing failure rates. Passive calcula-­‐ tions are handled well by the grid, but many applications require active services to coordinate the distributed analyses. Either scientists must provide their own resources for such services or negotiate with a particular site to provide them. This reduces the speed at which new calculations can be done. Virtualization technologies have matured rapidly over the last few years, provid-­‐ ing a mechanism for offering customized, uniform environments for users. This additional flexibility comes with negligible costs in terms of processing power, network bandwidth, and disk I/O in modern systems. Using grid technologies combined with virtualization will allow the grid to provide users with a homogeneous computing environment, simplifying applications and reduc-­ ing failures. In parallel with the increasing maturity of virtualization, cloud technologies have emerged. These technologies allow users to dynamically allocate computing re-­‐ sources (often in less than a minute) and to specify the characteristics for the al-­‐ located resources. The fusion of cloud and grid technologies would provide a more dynamic and flexible computing environment for grid application de-­ velopers. Cloud and virtualization technologies also offer other benefits to adminis-­ trators of resource centres, such as the migration of live services for load bal-­‐ ancing or the deployment of redundant servers. Reduced costs for managing re-­‐ sources immediately benefits users in freeing money for additional computing resources or in having better user support from administrators. A combined...
Sample 1
AutoNDA by SimpleDocs

Related to European Grid Initiative

  • MINISTRY INITIATIVES OSSTF/FEESO education workers will be an active participant in the consultation process at the Ministry Initiatives Committee. Ministry Initiatives Committee shall meet at least quarterly each year to discuss new initiatives, including implications for training, resources. C14.00 PROVINCIAL FEDERATION RELEASE DAYS

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • MINISTRY/SCHOOL BOARD INITIATIVES ETFO will be an active participant in the consultation process to develop a Ministry of Education PPM regarding Ministry/School Board Initiatives.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order.

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • STAGE The aggrieved may within twenty-one (21) calendar days after an occurrence, or in the case of disciplinary action within twenty-one (21) calendar days after same has been brought to the attention of the reduce the grievance to writing and accompanied by representatives of the Grievance Committee, take the matter up with the Fire Chief. The Fire Chief shall, within seven (7) calendar days, arrange a meeting place and time to discuss and attempt to settle the grievance. The Corporation will be represented at this stage of the grievance procedure by the Fire Chief and the Director of Human Resources. Grievancesthat are not settled within seven (7)calendar days of the meeting may be referred to Stage provided that not more than seven (7) calendar days have elapsed since the meeting at Stage STAGE2 The aggrieved shall reconsider the grievance and the Fire Chief's response at Stage and decide within five (5) calendar days whether to proceed with the grievance. If the aggrieved wishes to proceed, the Assistant City Manager of Emergency and Corporate Services, the Fire Chief, and the Director of Human Resources will meet with the aggrieved accompanied by representatives of the Grievance Committee within seven (7) calendar days of notification by the aggrieved Failing settlement at this stage, Stage of the grievance procedure may be invoked provided that no more than seven (7) calendar days have elapsed since the hearing at Stage STAGE The aggrieved accompanied by representatives of the Grievance Committee, may then take the written grievance to a committee of Council members. In the case of discharge, the grievance shall be heard by the entire Council. Failing settlement at this stage within fourteen (14) calendar days, then the grievance may be referredto Arbitration, as provided under the "Fire Protectionand Prevention Act Part as amended, provided that not more than thirty

  • Professional Development Program (a) The parties agree to continue a Professional Development Program for the maintenance and development of the faculty members' professional competence and effectiveness. It is agreed that maintenance of currency of subject knowledge, the improvement of performance of faculty duties, and the maintenance and improvement of professional competence, including instructional skills, are the primary professional development activities of faculty members.

Time is Money Join Law Insider Premium to draft better contracts faster.